Teens Oversleeping Post-Concussion May Have Worse Recovery
Kids and teens sleeping longer, even as little as an hour more, during the first week after a concussion were more likely to have worse cognitive and somatic symptoms. Sleeping longer was also linked to persistent symptoms and slower recovery.
METHODOLOGY:
Researchers used data from a randomized clinical trial that took place across three emergency pediatric departments in Ontario, Canada, over a 2-year period beginning in March 2017.
The study included 291 kids and teens between the ages of 10 and 18 years (median age, 13.2 years; 44% female) who received treatment for a concussion within 48 hours of injury.
Each patient wore an accelerometer on their waist 24 hours a day for 2 weeks and completed sleep logs to monitor sleep patterns.
Symptoms were tracked using the Health and Behavior Inventory (HBI), a questionnaire that measures cognitive and somatic symptoms at 1 , 2 , and 4 weeks following their concussion.
Symptom change was measured using conservative (z score ≥ 1.65) and liberal (z score ≥ 1.28) cutoffs; estimates were measured in HBI units.
TAKEAWAY:
Kids and teens who slept 10.5 vs 9.5 hours per night during the first week after a concussion had higher symptom scores at 1 week (estimate, 1.3; 95% CI, 0.25-2.28).
Longer sleep duration was linked to higher odds of persisting symptoms at 4 weeks (conservative: odds ratio [OR], 1.73; 95% CI, 0.91-3.26; liberal: OR, 1.93; 95% CI, 1.07-3.47).
Teens who slept 10.9 vs 9.9 hours were more likely to have increased symptoms at 4 weeks (estimate, 2.2; 95% CI, 0.85-3.47).
IN PRACTICE:
'Long sleep duration may be associated with increased odds of being reliably symptomatic at 4 weeks, therefore a greater risk of PSAC [persisting symptoms after a concussion],' the study authors wrote. 'Clinicians should monitor youths' sleep after concussion.'
SOURCE:
This study was led by Lauren Butterfield, MSc, of the Children's Hospital of Eastern Ontario Research Institute in Ottawa, Canada. It was published online on June 18 in JAMA Network Open.
LIMITATIONS:
The HBI used for symptom assessment is not validated for youths older than 16.99 years, and 16 participants were older than 17 years. Recruitment from three Canadian pediatric emergency departments may have introduced sampling bias.
DISCLOSURES:
Various study authors reported receiving stipend support, research grants, and travel awards from the Children's Hospital of Eastern Ontario Research Institute, the Canadian Institutes of Health Research, and the Canadian Concussion Network, among others.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
Real-world evidence study uses SnapshotNIR on 4,000+ wounds to deliver targeted care and improve wound healing outcomes
The retrospective study examines SnapshotNIR use on wounds in post-acute care, showing how tissue viability insights help improve plan of care for patients. 'Our pioneering, big data research in post-acute care settings using this point-of-care diagnostic technology enabled our providers to utilize data-driven decisions rather than relying on assumptions.'— Martha R. Kelso, RN, CHWS, DAPWCA, HBOT CALGARY, ALBERTA, CANADA, July 7, 2025 / / -- Kent Imaging, a leader in near-infrared spectroscopy (NIRS) medical imaging, is proud to share the publication in the Journal of Wound Care titled 'Utilization of Near Infrared Spectroscopy (NIRS) in Post-Acute Care: Analysis of Real-World Clinical Decision Making.' This is a pioneering study reporting real-world evidence of a data set of 19,192 wounds from 6,147 patients in post-acute care. The study provided the most comprehensive real-world evaluation of SnapshotNIR, analyzing its clinical application across 35% of the dataset, in 2,165 patients, and 4,060 wounds. The data highlighted how numerous providers, across 22 states of the US, selectively deployed SnapshotNIR in cases of clinical complexity, particularly when conventional wound care approaches had plateaued. SnapshotNIR directly impacted clinician's care plans for the imaged wounds including determining a wound goal as maintenance (20.76%), noting a wound goal as healable (17.39%), identifying the need for additional studies (11.60%), determining a wound goal as palliative (5.22%), and directing hospice referral (0.76%). The study found that providers used SnapshotNIR for care plan evaluation (92.98%), tissue oxygenation trending (66.65%), evaluation of the necessity and effectiveness of debridement (29.16%), and microcirculation or vascular referral assessment (8.89%). The NIRS-imaged group included patients with non-healing wounds, systemic disease burden, and vascular risk factors—populations in whom diagnostic uncertainty is high, and healing trajectories are difficult to predict. Martha R. Kelso, RN, CHWS, DAPWCA, Founder and Chief Regulatory Officer at Wound Care Plus, LLC, and primary author stated, 'Our pioneering, big data research in post-acute care settings using this point-of-care diagnostic technology enabled our providers to utilize data-driven decisions rather than relying on assumptions. Using SnapshotNIR as our premier choice for near-infrared spectroscopy has provided valuable insights into tissue perfusion beyond the limits of the naked eye with the wound and skin surface. Additionally, with Kent Imaging's SnapshotNIR, we can see inflammatory processes, oxygenation, and deoxygenation, helping us to confirm or change wound etiology in real-time without a care delay. This diagnostic device showed we could perform higher-quality debridements by getting down to viable tissue with adequate perfusion—a key step in wound healing. With visual NIR guidance, the clinicians at Wound Care Plus, LLC can perform diagnostics, debride, and perform other procedures with confidence, helping to heal more wounds more effectively.' 'SnapshotNIR has become an essential part of my daily workflow as a wound care clinician,' commented Erin Brunkan, FNP-C at Wound Care Plus LLC, and a co-author. She continued, 'It's like having a window into a wound's healing potential. Our goal is always to do our best clinical work to close a wound, and this publication highlighted how objective data from the device can drive a wound towards closure, with more confidence and clarity in our plan of care.' SnapshotNIR uses NIRS to assess tissue oxygenation by measuring the relative concentrations of oxygenated and deoxygenated hemoglobin within the microvasculature. This non-invasive, handheld imaging technology delivers instant, color-coded oxygenation maps assisting clinicians in their treatment planning. Unique to SnapshotNIR is the hemoglobin view, providing clinicians with additional insights into wound healing trends without the need for dyes, contact, or compression, at the point of care. Kelso added, 'Wound Care Plus, LLC adopted this technology company-wide in 2022 when these portable diagnostic devices passed our 'trunk-to-bed' test. A requirement I use to invest in diagnostic technologies is being able to take them right to the patient's bedside—meeting our need to facilitate on-the-spot assessments for perfusion. This data shows we are making a significant difference, healing more wounds, and providing appropriate certified plans of care to meet this underserved population. In Post-Acute Care, technology and advancements are often anemic or an afterthought by payors, despite being the demographic that needs it the most due to significant co-morbidities, polypharmacy, and a host of other challenges. This technology brings the diagnostic side of wound care out of the 1980s and into the millennia where we belong.' The study's results validated the targeted use of SnapshotNIR in a diverse patient population. It demonstrated healing rates of 36.5% for pressure ulcers, 38.15% for lower extremity wounds, and 39.68% for all wounds, compared to the previously published healing rate of 22.5% for the same practice when using standard of care. It represented an improvement of 62%–76% in healing rates compared to the previously published rate. 'The data showed that even in complex cases, we were able to shift wound goals from palliative to healable in numerous cases, which is a game-changer for the population we treat across the country,' noted Amanda R. Ohrt, MHA, AAPWCA, Chief Quality Officer at Wound Care Plus LLC, and co-author. 'For our mobile care patients, where every visit counts, SnapshotNIR gives us the insights we need to tailor treatments that actually work, allowing us to heal more wounds.' As this technology continues to gain traction in acute, post-acute, and outpatient settings, Kent Imaging remains committed to supporting ongoing research and provider education. Congratulations to the team of clinicians and researchers behind this publication. Special recognition to lead author Martha R. Kelso, RN, CHWS, DAPWCA, HBOT, and co-authors Amanda R. Ohrt, MHA, AAPWCA; Erin Brunkan, NP-C; Denise Flynn, AGNP-C; Lauren Riley, FNP-C; William H. Tettelbach, MD, FACP, FIDSA, FUHM, MAPWCA; Najratun Nayem Pinky, PhD; Debarpan Das, MSc; Jeffrey Niezgoda, MD, FACHM, MAPWCA, CHWS; and Jennie Feight, MS, CPC, CPMA, CPC-I. About Kent Imaging Kent Imaging, located in Calgary, Alberta, Canada, is a leading innovator in near-infrared tissue oxygenation imaging, which develops, manufactures, and markets medical technology that supports real-time decision-making in wound care, vascular and surgical subspecialties. Kent holds multiple patents in oxygen imaging technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. SnapshotNIR is supported by clinical evidence demonstrating its ability to help improve clinical decision-making in wound care and reduce healing time. Since receiving FDA and Health Canada clearance in 2017, the technology has been featured in several published articles and peer-reviewed posters. Applying the knowledge gained from clinical trials to patient care promotes consistency of treatment and optimal outcomes. Leah Pavlick Kent Imaging Inc. [email protected] Visit us on social media: LinkedIn Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Medscape
an hour ago
- Medscape
Extra Pneumococcal Dose Can Save Lives in Care Homes
TOPLINE: An additional dose of a pneumococcal vaccine, either 23-valent pneumococcal polysaccharide vaccine (PPV23) or 20-valent pneumococcal conjugate vaccine (PCV20), for new care home residents upon entry could prevent a substantially higher proportion of invasive pneumococcal disease cases and deaths per dose than the single-dose schedule for 65-year-olds, with the PCV20 vaccine demonstrating greater effectiveness over the PPV23 vaccine. METHODOLOGY: Researchers in England conducted an observational surveillance study to evaluate the effect of administering an additional dose of a pneumococcal vaccine, either PPV23 or PCV20, at admission to new residents of older care homes, alongside the routine vaccination. Using national invasive pneumococcal disease surveillance and other data sources, they analysed 121,587 new care home residents (83,271 women and 38,316 men) to estimate the potential number of invasive pneumococcal disease cases and deaths averted over 5 years and calculated the number needed to vaccinate (NNV) to prevent one vaccine-type case and one death. They compared these results with those of 603,109 individuals (aged 65 years) from the general population who had received a single vaccine dose. TAKEAWAY: PPV23 immunisation of all new care home residents would prevent 36% of PPV23-type lifetime cases of invasive pneumococcal disease (NNV, 687) and 48% of deaths (NNV, 1095). Similarly, PCV20 immunisation would prevent 75% of PCV20-type lifetime cases of invasive pneumococcal disease (NNV, 384) and 80% of deaths (NNV, 774). An additional dose of both vaccines could prevent five times more cases and 18 times more deaths than the current immunisation policy for adults aged 65 years. IN PRACTICE: "Protecting older adults, especially those in aged care facilities, from infectious diseases is necessary to reduce morbidity and mortality. Vaccination, including against pneumococcus, is an effective strategy to promote healthy ageing," the author of a commentary wrote. SOURCE: This study was led by Fariyo Abdullahi, MSc, Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, London, England. It was published online on July 01, 2025, in The Lancet Healthy Longevity. LIMITATIONS: The national dataset could not identify individuals in temporary or respite care, potentially leading to an undercount of care home residents. This study relied on invasive pneumococcal disease risk estimates from the older study, which may not have reflected current conditions in England. The NNV might be underestimated as frail residents are less likely to receive invasive investigations. DISCLOSURES: The Immunisation and Vaccine Preventable Diseases Division provided vaccine manufacturers with postmarketing surveillance reports on pneumococcal and meningococcal infections, with cost recovery charges applied. One author reported performing contract research for pharmaceutical companies on behalf of St George's University of London and the UK Health Security Agency without personal remuneration. The other authors reported having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
Archaeologists unveil 3,500-year-old city in Peru
Archaeologists have announced the discovery of an ancient city in Peru's northern Barranca province. The 3,500-year-old city, named Peñico, is believed to have served as a key trading hub connecting early Pacific coast communities with those living in the Andes mountains and Amazon basin. Located some 200km north of Lima, the site lies about 600 metres (1,970 feet) above sea level and is thought to have been founded between 1,800 and 1,500 BC - around the same time that early civilisations were flourishing in the Middle East and Asia. Researchers say the discovery sheds light on what became of the Americas' oldest civilisation, the Caral. Drone footage released by researchers shows a circular structure on a hillside terrace at the city's centre, surrounded by the remains of stone and mud buildings. Eight years of research at the site unearthed 18 structures, including ceremonial temples and residential complexes. In buildings at the site, researchers discovered ceremonial objects, clay sculptures of human and animal figures and necklaces made from beads and seashells. Peñico is situated close to where Caral, recognised as the oldest known civilisation in the Americas, was established 5,000 years ago at around 3,000 BC in the Supe valley of Peru. Caral features 32 monuments, including large pyramid structures, sophisticated irrigation agriculture and urban settlements. It is believed to have developed in isolation to other comparative early civilisations in India, Egypt, Sumeria and China. Dr Ruth Shady, the archaeologist who led the recent research into Peñico and the excavation of Caral in the 1990s, said that the discovery was important for understanding what became of the Caral civilisation after it was decimated by climate change. The Peñico community was "situated in a strategic location for trade, for exchange with societies from the coast, the highlands and the jungle", Dr Shady told the Reuters news agency. At a news conference unveiling the findings on Thursday, archaeologist Marco Machacuay, a researcher with the Ministry of Culture, said that Peñico's significance lies in it being a continuation of the Caral society. Peru is home to many of the Americas' most significant archaeological discoveries, including the Inca citadel of Machu Picchu in the Andes and the mysterious Nazca Lines etched into the desert along the central coast. Researchers help uncover ancient Egyptian city Iron Age settlement and 'Roman villa' unearthed Bronze Age burial site found under park
